Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications[E8]

Do aviso

Call: Cluster 1 - Health (Single stage - 2027/1). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: Patients benefit from decreased incidence of Adverse Drug Reactions (ADRs) caused by the administration of multiple medications (three or more medicinal products [1] ) and enhanced health outcomes by ensuring safer and more effective use of medication. Healthcare professionals can adopt adverse drug reactions prevention and reduction strategies to integrate genetic and other biomarker information into clinical decision-making to optimise the use of medication, especially in situations of comorbidities. Healthcare systems benefit from cost savings thanks to reduced hospital admissions and other costs associated with ADRs related to the intake of multiple medicines. Clinical and regulatory guidelines and policies for medication management in case of multiple medications can be revised supported by robust evidence. Educational programs for healthcare providers and patients benefit from improved awareness and management of polypharmacy and ADRs. Scope: While medicinal products contribute considerably to the health of EU citizens, they can also have adverse reactions. It is estimated that ar…[E3]

Os detalhes do aviso aparecem como a fonte publicou. Os fatos e requisitos que extraímos estão em inglês.

• Aberto aUniversities and research. Classificado pelo SLETOR a partir das palavras do edital.
• CondiçãoEU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]

• RiscoThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
• DesconhecidoWe read the funder's listing, not the full guidance or application forms.

1. Aberta a propostas · 29 de out. de 2026, 07:41 UTC

   The funder published the call with a future closing date.

   Alterado: status, notice type, published at (registro de origem Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02))

2. Vista pela primeira vez · 28 de out. de 2026, 21:22 UTC

   The funder announced the call. Applications have not opened yet.

   Registro de origem: Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02)

Cada dado desta página vem do edital do financiador. Cada item mostra o registro e o campo de onde foi lido.

1. E1

   The funder is European Commission.

   De Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), campo /metadata/type/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

2. E2

   Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

   “2027-02-17T00:00:00.000+0000”

   De Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), campo /metadata/deadlineDate/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

3. E3

   The buyer describes the requirement in the notice.

   “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to d…”

   De Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), campo /metadata/descriptionByte/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

4. E4

   EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

   “EU call topic”

   De Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), campo /metadata/type/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

5. E5

   This is an EU call for proposals.

   “31094502”

   De Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), campo /metadata/status/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

6. E6

   Applications open on 29 Oct 2026.

   “2026-10-29T00:00:00.000+0000”

   De Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), campo /metadata/startDate/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

7. E7

   The Funding & Tenders Portal gives the status as open for submission.

   De Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), campo /metadata/status/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

8. E8

   The notice is titled "Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications".

   De Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), campo /metadata/title/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

9. E9

   The EU contribution per grant is up to EUR 11,000,000 (from EUR 3,000,000).

   De Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), campo /metadata/budgetOverview/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. Licença dos dados: Creative Commons Attribution 4.0 (European Commission) ↗ (abre em nova aba). Dados de contato pessoais dos avisos não são guardados nem exibidos.